ARCHIVES

Guest Editorial: Once Again, Hype Overshadows Data In Breast Cancer Screening Debate

This article is from The Cancer Letter archive.

Vol. 40 No. 07 | February 14, 2014

Download PDF Visit The Full Archive

Related Articles

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

ASCO Members asked To Help In Planning

August 26, 1988

Cancer.gov Knocked Offline By Theft Of Routers

July 11, 2003

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

CCRAC Approves New Grant Program For Studies Of Cancer Patient Compliance RFA to Be Issued

May 16, 1980

House Subcommittee Passes Bush Request for NIH, NCI Budgets.

June 9, 2006